CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-03-24 | Shaaltiel Yoseph Executive VP, R&D | Sale | −202,700 | $7.08 | $1.4M | 933,754 |
| 2010-03-23 | Shaaltiel Yoseph Executive VP, R&D | Sale | −127,300 | $7.02 | $894K | 1,136,454 |
| 2010-02-25 | Maimon Yossi VP, Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +130,000 | 130,000 | ||
| 2010-02-25 | Shaaltiel Yoseph Executive VP, R&D | Grant or award · Stock Options (Right to Buy) | +145,000 | 145,000 | ||
| 2010-02-25 | Aviezer David President & CEO | Grant or award · Stock Options (Right to Buy) | +250,000 | 250,000 | ||
| 2010-02-25 | Almon Einat Brill VP, Product Development | Grant or award · Stock Options (Right to Buy) | +130,000 | 130,000 | ||
| 2010-02-07 | Lauterbach Sandra Leigh VP, Sales & Commercial Affairs | Grant or award · Stock Options (Right to Buy) | +160,000 | 160,000 | ||
| 2009-12-02 | Bar-Shalev Amos Director | Purchase | +1,000 | $8.68 | $9K | 1,000 |
| 2009-12-02 | Bar-Shalev Amos Director | Purchase | +680 | $8.20 | $6K | 1,680 |
| 2009-11-12 | Hurvitz Eli Director | Sale | −1,121,967 | $10.00 | $11.2M | 1,764,480 |
| 2009-11-12 | Hurvitz Eli Director | Sale | −250,000 | $10.76 | $2.7M | 1,514,480 |
| 2009-11-12 | Hurvitz Eli Director | Option exercise | +3,384,502 | $0.00 | $3K | 4,898,982 |
| 2009-11-12 | Hurvitz Eli Director | Shares withheld for taxes | −299 | $11.33 | $3K | 4,898,683 |
| 2009-11-12 | Hurvitz Eli Director | Other disposition | −4,443,443 | 455,240 | ||
| 2009-11-12 | Hurvitz Eli Director | Option exercise · Stock Options (Right to Buy) | −3,384,502 | 0 | ||
| 2009-10-21 | Aviezer David CEO and President | Sale | −34,238 | $9.36 | $320K | 0 |
| 2009-10-21 | Aviezer David CEO and President | Option exercise | +247,490 | $0.12 | $30K | 0 |
| 2009-10-21 | Aviezer David CEO and President | Shares withheld for taxes | −3,253 | $9.13 | $30K | 0 |
| 2009-10-21 | Aviezer David CEO and President | Option exercise · Stock Options (Right to Buy) | −247,490 | 326,267 | ||
| 2009-10-20 | Aviezer David CEO and President | Sale | −60,000 | $9.45 | $567K | 0 |
Page 10 of 33 · 654 trades